This summary has been written by GSK with consultation and approval from the Collaborative Working Project Team.

Bury GP Federation and GSK are undertaking a Collaborative Working project.

The aim of the project is to support the increased uptake of the Shingles National Immunisation Programme (NIP) across Bury GP Federation and increase understanding on how to do this effectively, particularly across a larger population (such as a GP Federation).

The engagement of a dedicated Project Manager (PM) to identify barriers and opportunities to effective implementation, project manage the delivery of the identified solutions and measure and evaluate the impact, is expected to result in the primary objective of increasing the uptake of Shingles vaccination within patients eligible under the Shingles NIP.

The aims of the project are to:
- Deliver a deep dive into the specific barriers and opportunities for effective NIP implementation across Bury GP Federation in order to increase understanding specific to Bury and across similar geographies.
- Creation of a solutions specification to document and evaluate identified solutions.
- Test, measure, optimise identified solutions.
- Increase Shingles vaccination within the NIP eligibility criteria across Bury GP federation in line with, as a minimum, the national average for the routine and catchup cohort and QOF indicators.
- Ensure alignment of Shingles vaccine administration in line with the GreenBook Chapter 28a Shingles (herpes zoster) guidance.
- Improve health outcomes through increased Shingles vaccination uptake.

In achieving these goals, the project should:
- Reduce health inequalities and patient suffering from Shingles and its associated complications by supporting increased vaccination levels, in line with the NIP eligibility criteria, within an area of reduced uptake.
- Create a sustaining legacy of effective vaccination uptake by enhancing knowledge, capability and effective ways of working across Bury GP federation.
- Support broader NHS uptake in the Shingles NIP and broader vaccination initiatives through documentation, publication and distribution of project methodology and outputs.
- Reduce the longer-term burden caused by complications of Shingles on practices across the GP Federation through the reduction in the prevalence Shingles across the patient population.

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from December 2022 to April 2023.

The collaborative working project is non-promotional and the neither GSK nor the PM will be directly involved with prescribing decisions or have any clinical interaction directly with patients.

Intended Benefits:

Patient:
- Increase protection from Shingles, likely resulting in improved health outcomes through greater uptake of vaccination.
- Fewer Shingles cases and Shingles related complications, which could lead to fewer hospitalisations and development of chronic pain.
GlaxoSmithKline UK Ltd (GSK) and Bury GP Federation Collaborative Working Executive Summary
Shingles National Immunisation Programme Improvement Project

- Increased patient vaccination engagement and awareness of vaccination could result in a more informed patient population resulting in broader vaccination uptake across other national immunisation programmes and subsequent protection.
- Improved experience of the healthcare system through engaging in improved vaccination service provision.

NHS (Bury GP Federation):
- Dedicated project management support.
- More effective use of resources to vaccinate at scale and pace across the larger population of the GP federation.
- Dedicated focus on challenges specific to the Federation’s population, including demographic specific challenges and opportunities, of which bespoke solutions could be developed.
- Opportunity to upskill workforce across the federation in project management skills, resulting in increased capability which could result in sustained uptake improvements and be transferable to the implementation of other programmes.
- Reduced prevalence of Shingles resulting in reduced healthcare utilisation in both primary care and any associated complications and hospitalisations.
- Increased uptake of Shingles vaccination in line with national guidance and expectations.
- Improved patient satisfaction with services across the GP federation.
- Improved achievement of national voluntary annual directed quality indicator.

GSK:
- Increase understanding of key challenges and opportunities faced in the NHS in delivering high quality and effective vaccination programmes.
- Test and measure solutions for Shingles vaccination which can be shared wider in order to support greater uptake of Shingles vaccination.
- Identification of practice level coverage of Shingles vaccination data at all ages within the NIP eligibility criteria.
- Demonstrate effectiveness of collaborative working and implementation of vaccination across larger populations.
- Increased utilisation of GSK’s Shingles vaccine, as well as those of other pharmaceutical companies, in appropriate patients.
- Helps GSK to live its values of being a patient-focussed company